Patients with major depression ( DSM-IV diagnostic criteria ) scoring over 17 points on the 17-item Hamilton Depression Scale ( HAM-D ) and over 21 points on the Montgomery-Asberg Depression Rating Scale ( MADRS ) were recruited and randomised to receive milnacipran ( 50 mg/day increasing after 1 week to 100 mg/day ) or fluoxetine ( 20 mg/day ) for 6 weeks .
